Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) a leader in the development of RNAi-based therapeutics announced that Douglas M. Fambrough PhD President and CEO will present at Jefferies 2014 Global Healthcare Conference on June 2 2014 at 10:00am ET in New York NY. In addition Dr. Fambrough will participate in the 2014 Biopharma: Trends to Watch panel at the Boston CEO Conference on June 4 2014 at 10:00am ET in Boston MA. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) weekly performance is 9.65%. On last trading day company shares ended up $17.73. Analysts mean target price for the company is $48.25. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) distance from 50-day simple moving average (SMA50) is -21.72%.
On May 14, 2014, Concert Pharmaceuticals, Inc. (NYSE:JMPC) announced its financial results for the quarter ended March 31, 2014. Concert Pharmaceuticals Inc. (NYSE:JMPC) shares fell -0.04% in last trading session and ended the day on $25.29. JMPC return on assets is -64.60%. Concert Pharmaceuticals Inc. (NYSE:JMPC) quarterly performance is 41.95%.
Citigroup Inc. restated their buy rating on shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a report released on Wednesday, AnalystRatings. Ambit Biosciences Corp (NASDAQ:AMBI) shares moved up 10.02% in last trading session and was closed at $6.97, while trading in range of $6.42 – $7.35. Ambit Biosciences Corp (NASDAQ:AMBI) year to date (YTD) performance is -27.65%.
Research analysts at Roth Capital cut their price target on shares of Kindred Biosciences (NYSE:KIN) from $18.00 to $17.00 in a report released on Tuesday, ARN reports. Kindred Biosciences Inc. (NASDAQ:KIN) ended the last trading day at $18.11. Company weekly volatility is calculated as 5.67% and price to cash ratio as 5.46.Kindred Biosciences Inc. (NASDAQ:KIN) showed a positive weekly performance of 19.14%.
RXi Pharmaceuticals Corp. (NASDAQ:RXII) a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced that it received the notice of allowance from the U.S. Patent and Trademark Office on its novel, self-delivering RNAi platform (sd rxRNA). RXi Pharmaceuticals Corp (NASDAQ:RXII) weekly performance is -2.00%. On last trading day company shares ended up $2.94. Analysts mean target price for the company is $11.25. RXi Pharmaceuticals Corp (NASDAQ:RXII) distance from 50-day simple moving average (SMA50) is -24.20%.